MultiCell Technologies, Inc.

MultiCell is a leading-edge biopharmaceutical company committed to the development and commercialization of breakthrough therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms.

MultiCell leverages patented methods of modulating the human immune system to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and other health threats. Currently, the market for therapies addressing such conditions is estimated at $8 billion worldwide.

The Company's novel technologies include expertise in Toll-like receptors and T-cell targeting to modulate both the innate and adaptive immune systems, enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting of the immune system.